Total Payments
$359,924
2024 Payments
$40,277
Companies
19
Transactions
502
Medicare Patients
984
Medicare Billing
$124,921
Payment Breakdown by Category
Other$298,854 (83.0%)
Travel$29,201 (8.1%)
Food & Beverage$18,413 (5.1%)
Consulting$13,400 (3.7%)
Education$56.06 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $234,874 | 91 | 65.3% |
| Travel and Lodging | $29,201 | 126 | 8.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $23,000 | 8 | 6.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,240 | 8 | 5.9% |
| Honoraria | $19,740 | 16 | 5.5% |
| Food and Beverage | $18,413 | 240 | 5.1% |
| Consulting Fee | $13,400 | 8 | 3.7% |
| Education | $56.06 | 5 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $186,441 | 238 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $59,343 | 69 | $0 (2024) |
| ABBVIE INC. | $45,193 | 85 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $21,483 | 15 | $0 (2023) |
| Madrigal Pharmaceuticals | $18,910 | 20 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16,869 | 21 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $7,538 | 10 | $0 (2018) |
| Valeant Pharmaceuticals North America LLC | $1,844 | 21 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,100 | 1 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $297.39 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,277 | 52 | Madrigal Pharmaceuticals ($18,910) |
| 2023 | $42,361 | 33 | Mallinckrodt Hospital Products Inc. ($20,687) |
| 2022 | $49,948 | 65 | Gilead Sciences, Inc. ($30,464) |
| 2021 | $25,143 | 26 | Gilead Sciences, Inc. ($14,931) |
| 2020 | $20,148 | 28 | Gilead Sciences, Inc. ($13,458) |
| 2019 | $53,627 | 73 | Gilead Sciences, Inc. ($36,862) |
| 2018 | $66,581 | 86 | Gilead Sciences, Inc. ($35,314) |
| 2017 | $61,840 | 139 | Gilead Sciences Inc ($30,458) |
All Payment Transactions
502 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,583.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $701.95 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $306.11 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $145.53 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $137.48 | General |
| Category: LIVER DISEASE | ||||||
| 11/25/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | Cash or cash equivalent | $9.79 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.31 | General |
| Category: Gastroenterology | ||||||
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $134.84 | General |
| Category: LIVER DISEASE | ||||||
| 11/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $144.84 | General |
| Category: INFLAM | ||||||
| 11/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $122.24 | General |
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $124.90 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: INFLAM | ||||||
| 10/22/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,030.00 | General |
| 10/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Gastroenterology | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $133.01 | General |
| 10/07/2024 | CapsoVision, Inc. | CapsoCam Plus (Device) | Food and Beverage | Cash or cash equivalent | $158.25 | General |
| Category: Gastroenterology | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $401.68 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $186.86 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | Cash or cash equivalent | $181.56 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $104.33 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $94.62 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 287 | 453 | $141,080 | $35,057 |
| 2022 | 5 | 212 | 371 | $112,002 | $28,868 |
| 2021 | 6 | 228 | 439 | $114,852 | $30,014 |
| 2020 | 7 | 257 | 539 | $112,481 | $30,982 |
Total Patients
984
Total Services
1,802
Medicare Billing
$124,921
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 73 | 103 | $43,363 | $11,430 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 112 | $32,704 | $8,695 | 26.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 52 | 146 | $22,046 | $6,484 | 29.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $14,124 | $3,075 | 21.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $6,396 | $1,469 | 23.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 11 | 12 | $6,720 | $1,191 | 17.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $5,489 | $1,175 | 21.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 16 | 18 | $6,498 | $1,026 | 15.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 13 | 17 | $3,740 | $512.42 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 64 | 99 | $41,679 | $11,203 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 69 | 111 | $32,412 | $8,986 | 27.7% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 42 | 123 | $18,573 | $4,512 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $12,840 | $2,998 | 23.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 18 | $6,498 | $1,169 | 18.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 65 | 84 | $35,364 | $9,653 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 63 | 101 | $29,492 | $8,441 | 28.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 60 | 212 | $32,012 | $7,610 | 23.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $8,988 | $2,305 | 25.6% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 14 | 14 | $6,986 | $1,478 | 21.2% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 12 | 14 | $2,010 | $527.12 | 26.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 61 | 278 | $40,333 | $10,459 | 25.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 48 | 72 | $28,139 | $7,040 | 25.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 78 | 104 | $28,618 | $6,574 | 23.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 16 | 22 | $3,797 | $2,304 | 60.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 15 | 16 | $8,286 | $2,070 | 25.0% |
About Dr. David Wolf, MD
Dr. David Wolf, MD is a Transplant Hepatology healthcare provider based in Valhalla, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801998950.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Wolf, MD has received a total of $359,924 in payments from pharmaceutical and medical device companies, with $40,277 received in 2024. These payments were reported across 502 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($234,874).
As a Medicare-enrolled provider, Wolf has provided services to 984 Medicare beneficiaries, totaling 1,802 services with total Medicare billing of $124,921. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Transplant Hepatology
- Other Specialties Gastroenterology
- Location Valhalla, NY
- Active Since 09/01/2006
- Last Updated 11/30/2021
- Taxonomy Code 207RT0003X
- Entity Type Individual
- NPI Number 1801998950
Products in Payments
- Epclusa (Drug) $85,553
- OCALIVA (Drug) $54,177
- Vemlidy (Drug) $46,645
- Mavyret (Drug) $25,402
- TERLIVAZ (Drug) $21,483
- REZDIFFRA (Drug) $18,776
- XIFAXAN (Drug) $18,442
- MAVYRET (Drug) $11,157
- Viekira (Drug) $8,101
- ZEPATIER (Drug) $7,413
- OCA (Drug) $5,160
- Vosevi (Drug) $4,951
- Stivarga (Drug) $1,100
- Livdelzi (Drug) $294.84
- CREON (Drug) $196.84
- CapsoCam Plus (Device) $158.25
- RESMETIROM (Drug) $134.84
- EXALT Model D (Device) $134.57
- INVOKANA (Drug) $125.00
- DIFICID (Drug) $124.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.